Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.
暂无分享，去创建一个
R. Collins | M. Konopleva | Z. Estrov | M. Andreeff | H. Kantarjian | G. Garcia-Manero | J. Cortes | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | M. Levis | N. Pemmaraju | A. Perl | Blake Pond | M. Vusirikala | P. Patel | A. Ramachandran | Jamil Paradela